{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:35Z","timestamp":1790712575474,"version":"4.1.0"},"reference-count":283,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic drug monitoring (TDM) is essential for optimizing systemic antifungal therapy, particularly for agents with narrow therapeutic windows, variable pharmacokinetics (PK) or established exposure\u2013response relationships. By enabling individualized dosing, TDM improves efficacy, reduces toxicity and helps prevent resistance. This review synthesizes current evidence and recommendations for antifungal TDM across available and emerging agents, including triazoles, flucytosine, echinocandins, amphotericin B, and novel therapies such as ibrexafungerp, olorofim and fosmanogepix. Voriconazole, posaconazole and itraconazole exhibit substantial interpatient variability and concentration-dependent toxicity, supporting routine TDM. Fluconazole is generally predictable but may warrant monitoring in critically ill patients, those on renal replacement therapy, or with central nervous system infections, though empiric dose escalation is often more practical. Isavuconazole has more stable PK, limiting TDM to select high-risk scenarios. Flucytosine requires TDM due to its narrow therapeutic index and resistance risk, particularly in renal impairment. Echinocandins are safe, but critically ill or obese patients may be underexposed, warranting empiric dose adjustments over routine TDM. Liposomal amphotericin B exhibits complex PK with plasma concentrations poorly reflecting active drug, precluding reliable TDM. Emerging antifungals lack sufficient data to support routine TDM. Despite strong justification, real-world utilization remains inconsistent, constrained by access, logistics and interpretive challenges. Expanding timely access, standardizing protocols and developing consensus-driven guidance, while using empiric dosing strategies where appropriate, are essential to ensure safe, effective and individualized antifungal therapy.<\/jats:p>","DOI":"10.1093\/jac\/dkag055","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:44:19Z","timestamp":1770209059000},"source":"Crossref","is-referenced-by-count":5,"title":["Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B","family":"Chastain","sequence":"first","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy , 914 New Bailie Street, HM Bldg, Room 116, Augusta, GA 30912 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-7477","authenticated-orcid":false,"given":"Daniel T","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Medical College of Georgia , Augusta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Eudy","sequence":"additional","affiliation":[{"name":"WellStar MCG Health Department of Pharmacy, , Augusta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-8652","authenticated-orcid":false,"given":"Andr\u00e9s F","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado , Anschutz Medical Campus, Aurora, CO 80045","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-1144","authenticated-orcid":false,"given":"David B","family":"Cluck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University , Johnson City, TN 37614 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026021706322656600_dkag055-B1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2026021706322656600_dkag055-B4","doi-asserted-by":"publisher","first-page":"i27","DOI":"10.1093\/cid\/ciaf256","article-title":"2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on histoplasmosis: treatment of asymptomatic histoplasma pulmonary nodules (histoplasmomas) and mild or moderate acute pulmonary histoplasmosis in adults, children, and pregnant people","volume":"81","author":"Arnold","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B5","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2026021706322656600_dkag055-B9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/jac\/dkac160","article-title":"Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults","volume":"77","author":"Chen","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B10","doi-asserted-by":"publisher","first-page":"e01554-20","DOI":"10.1128\/AAC.01554-20","article-title":"Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients","volume":"65","author":"Boonstra","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B11","doi-asserted-by":"publisher","first-page":"e00984-20","DOI":"10.1128\/AAC.00984-20","article-title":"Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing","volume":"64","author":"Muilwijk","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"2026021706322656600_dkag055-B13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00134-025-07793-5","article-title":"Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study","volume":"51","author":"Roberts","year":"2025","journal-title":"Intensive Care Med"},{"key":"2026021706322656600_dkag055-B14","doi-asserted-by":"publisher","first-page":"e0099124","DOI":"10.1128\/aac.00991-24","article-title":"Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections","volume":"68","author":"Matusik","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B15","doi-asserted-by":"publisher","first-page":"104630","DOI":"10.1016\/j.idnow.2022.10.002","article-title":"Suboptimal exposure to fluconazole in critically ill patients: pharmacokinetic analysis and determinants","volume":"53","author":"Bienvenu","year":"2023","journal-title":"Infect Dis Now"},{"key":"2026021706322656600_dkag055-B16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/microorganisms10010009","article-title":"Pharmacokinetic variability and target attainment of fluconazole in critically ill patients","volume":"9","author":"Van Daele","year":"2021","journal-title":"Microorganisms"},{"key":"2026021706322656600_dkag055-B17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10096-021-04201-w","article-title":"Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy","volume":"40","author":"Sandaradura","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026021706322656600_dkag055-B18","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1128\/AAC.00116-08","article-title":"Association of fluconazole pharmacodynamics with mortality in patients with candidemia","volume":"52","author":"Baddley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B19","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/jac\/dku169","article-title":"Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis","volume":"69","author":"Pea","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B20","author":"EUCAST"},{"key":"2026021706322656600_dkag055-B21","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1128\/AAC.49.8.3171-3177.2005","article-title":"Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia","volume":"49","author":"Clancy","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40121-020-00280-y","article-title":"Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome?","volume":"9","author":"Vena","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2026021706322656600_dkag055-B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/172.2.599","article-title":"Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections","volume":"172","author":"Anaissie","year":"1995","journal-title":"J Infect Dis"},{"key":"2026021706322656600_dkag055-B24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1439-0507.1997.tb00231.x","article-title":"High-dose therapy with fluconazole &gt; or = 800\u2005mg day-1","volume":"40","author":"Duswald","year":"1997","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s100960050252","article-title":"High-dose fluconazole therapy in patients with severe fungal infections","volume":"18","author":"Voss","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026021706322656600_dkag055-B26","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/cid\/ciab512","article-title":"Treatment practices for adults with candidemia at 9 active surveillance sites-United States, 2017\u20132018","volume":"73","author":"Gold","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B27","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1093\/mmy\/myy029","article-title":"Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis","volume":"57","author":"Thompson","year":"2019","journal-title":"Med Mycol"},{"key":"2026021706322656600_dkag055-B28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jamadermatol.2022.3745","article-title":"Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis\/cruris: a randomized clinical trial","volume":"158","author":"Khurana","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026021706322656600_dkag055-B29","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B30","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B31","doi-asserted-by":"publisher","first-page":"e00400-20","DOI":"10.1128\/AAC.00400-20","article-title":"Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults","volume":"64","author":"Thompson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B32","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dkz303","article-title":"Clinical experience with new formulation SUBA(R)-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies","volume":"74","author":"Nield","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B33","author":"Pharma"},{"key":"2026021706322656600_dkag055-B34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: an overview","volume":"32 Suppl 1","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B35","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1128\/AAC.38.7.1561","article-title":"Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards","volume":"38","author":"Law","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B36","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/AAC.37.10.2224","article-title":"Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations","volume":"37","author":"Hostetler","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B37","doi-asserted-by":"publisher","first-page":"e02353-20","DOI":"10.1128\/AAC.02353-20","article-title":"Variability of hydroxy-itraconazole in relation to itraconazole bloodstream concentrations","volume":"65","author":"Wiederhold","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32 Suppl 1","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B40","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1093\/clinids\/9.Supplement_1.S94","article-title":"Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies","volume":"9 Suppl 1","author":"Tricot","year":"1987","journal-title":"Rev Infect Dis"},{"key":"2026021706322656600_dkag055-B41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J Clin Pathol"},{"key":"2026021706322656600_dkag055-B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jac\/45.1.95","article-title":"Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules","volume":"45","author":"Cross","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B44","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa1613306","article-title":"A trial of itraconazole or amphotericin B for HIV-associated talaromycosis","volume":"376","author":"Le","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021706322656600_dkag055-B45","doi-asserted-by":"publisher","first-page":"e0063621","DOI":"10.1128\/AAC.00636-21","article-title":"Population pharmacokinetics and pharmacodynamics of itraconazole for disseminated infection caused by Talaromyces marneffei","volume":"65","author":"Stott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026021706322656600_dkag055-B47","doi-asserted-by":"publisher","first-page":"ofae010","DOI":"10.1093\/ofid\/ofae010","article-title":"MSG-15: super-bioavailability itraconazole versus conventional itraconazole in the treatment of endemic mycoses-a multicenter, open-label, randomized comparative trial","volume":"11","author":"Spec","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B48","doi-asserted-by":"publisher","first-page":"e13587","DOI":"10.1111\/tid.13587","article-title":"A novel highly bio-available itraconazole formulation (SUBA(R)-itraconazole) for anti-fungal prophylaxis in lung transplant recipients","volume":"23","author":"Whitmore","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2026021706322656600_dkag055-B49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2026021706322656600_dkag055-B50","doi-asserted-by":"publisher","first-page":"272376","DOI":"10.1152\/ajplegacy.1975.229.3.570","article-title":"Sporotrichosis: an overview and therapeutic options","volume":"2014","author":"Mahajan","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"2026021706322656600_dkag055-B51","doi-asserted-by":"publisher","first-page":"e0166821","DOI":"10.1128\/AAC.01668-21","article-title":"Antifungal therapy with azoles induced the syndrome of acquired apparent mineralocorticoid excess: a literature and database analysis","volume":"66","author":"Ji","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s002280050438","article-title":"Effect of omeprazole on the pharmacokinetics of itraconazole","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2026021706322656600_dkag055-B53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/0009-9236(95)90017-9","article-title":"Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin","volume":"58","author":"Ducharme","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"2026021706322656600_dkag055-B54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s002280050437","article-title":"Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2026021706322656600_dkag055-B55","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2026021706322656600_dkag055-B57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20 Suppl 3","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B58","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026021706322656600_dkag055-B59","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B62","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40780-021-00237-4","article-title":"Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report","volume":"8","author":"Kaneko","year":"2022","journal-title":"J Pharm Health Care Sci"},{"key":"2026021706322656600_dkag055-B64","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1128\/AAC.00504-10","article-title":"Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients","volume":"54","author":"Han","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/jcpt.13352","article-title":"Influence of switching from intravenous to oral administration on serum voriconazole concentration","volume":"46","author":"Harada","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026021706322656600_dkag055-B66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijantimicag.2016.10.010","article-title":"Bioavailability of voriconazole in hospitalised patients","volume":"49","author":"Veringa","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1128\/AAC.00949-10","article-title":"Human tissue distribution of voriconazole","volume":"55","author":"Weiler","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B68","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"2026021706322656600_dkag055-B69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2026021706322656600_dkag055-B70","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2026021706322656600_dkag055-B72","doi-asserted-by":"publisher","first-page":"748769","DOI":"10.3389\/fmed.2021.748769","article-title":"Effects of ex vivo extracorporeal membrane oxygenation circuits on sequestration of antimicrobial agents","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026021706322656600_dkag055-B73","doi-asserted-by":"publisher","first-page":"972585","DOI":"10.3389\/fphar.2022.972585","article-title":"Impact of extracorporeal membrane oxygenation on voriconazole plasma concentrations: a retrospective study","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026021706322656600_dkag055-B74","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/antibiotics12071100","article-title":"Voriconazole pharmacokinetics in critically ill patients and extracorporeal membrane oxygenation support: a retrospective comparative case-control study","volume":"12","author":"Ronda","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026021706322656600_dkag055-B75","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/microorganisms9071543","article-title":"A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation","volume":"9","author":"Van Daele","year":"2021","journal-title":"Microorganisms"},{"key":"2026021706322656600_dkag055-B76","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B78","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B79","doi-asserted-by":"publisher","first-page":"e0260656","DOI":"10.1371\/journal.pone.0260656","article-title":"Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients","volume":"16","author":"Bienvenu","year":"2021","journal-title":"PLoS One"},{"key":"2026021706322656600_dkag055-B80","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/antibiotics12040764","article-title":"Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-associated pulmonary aspergillosis","volume":"12","author":"Gatti","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026021706322656600_dkag055-B81","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026021706322656600_dkag055-B82","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B83","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bcpt.13465","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026021706322656600_dkag055-B84","doi-asserted-by":"publisher","first-page":"106711","DOI":"10.1016\/j.ijantimicag.2023.106711","article-title":"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial","volume":"61","author":"Veringa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B85","doi-asserted-by":"publisher","first-page":"106853","DOI":"10.1016\/j.ijantimicag.2023.106853","article-title":"Comment on \u2018Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial\u2019","volume":"62","author":"Gautier-Veyret","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B86","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B87","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B89","doi-asserted-by":"publisher","first-page":"e01491-16","DOI":"10.1128\/AAC.01491-16","article-title":"Pharmacodynamics of voriconazole against wild-type and azole-resistant Aspergillus flavus isolates in a nonneutropenic murine model of disseminated aspergillosis","volume":"61","author":"Rudramurthy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B90","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B91","doi-asserted-by":"publisher","first-page":"e02516-17","DOI":"10.1128\/AAC.02516-17","article-title":"Pharmacodynamics of voriconazole for invasive pulmonary scedosporiosis","volume":"62","author":"Box","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B92","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/13693786.2011.630039","article-title":"Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients","volume":"50","author":"Gomez-Lopez","year":"2012","journal-title":"Med Mycol"},{"key":"2026021706322656600_dkag055-B93","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B94","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B95","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B96","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B97","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B98","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"2026021706322656600_dkag055-B99","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1128\/AAC.01111-12","article-title":"Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis","volume":"56","author":"Jeans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B100","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis","volume":"11","author":"Seyedmousavi","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026021706322656600_dkag055-B101","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B102","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2026021706322656600_dkag055-B103","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/tcrm.2006.2.2.129","article-title":"Voriconazole in the management of nosocomial invasive fungal infections","volume":"2","author":"Peman","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2026021706322656600_dkag055-B104","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B105","doi-asserted-by":"publisher","first-page":"739","DOI":"10.4414\/smw.2006.11547","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"2026021706322656600_dkag055-B106","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1086\/374248","article-title":"Safety of voriconazole and dose individualization","volume":"36","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B107","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1248\/yakushi.128.1811","article-title":"Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection","volume":"128","author":"Okuda","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"2026021706322656600_dkag055-B108","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2026021706322656600_dkag055-B109","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"2026021706322656600_dkag055-B110","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/13693786.2011.587210","article-title":"Voriconazole-associated severe hyponatremia","volume":"50","author":"Kim","year":"2012","journal-title":"Med Mycol"},{"key":"2026021706322656600_dkag055-B111","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B112","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000359952","article-title":"Effects of multiple doses of voriconazole on the vision of healthy volunteers: a double-blind, placebo-controlled study","volume":"52","author":"Zrenner","year":"2014","journal-title":"Ophthalmic Res"},{"key":"2026021706322656600_dkag055-B114","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cmi.2016.12.031","article-title":"How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels?","volume":"23","author":"Heo","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51 Suppl 7","author":"Chau","year":"2021","journal-title":"Intern Med J"},{"key":"2026021706322656600_dkag055-B116","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026021706322656600_dkag055-B117","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026021706322656600_dkag055-B118","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B119","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/myc.13570","article-title":"Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection","volume":"66","author":"Boglione-Kerrien","year":"2023","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B120","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/FTD.0000000000000441","article-title":"Relationship between the CYP2C19 phenotype using the voriconazole-to-voriconazole N-oxide plasma concentration ratio and demographic and clinical characteristics of Japanese patients with different CYP2C19 genotypes","volume":"39","author":"Niioka","year":"2017","journal-title":"Ther Drug Monit"},{"key":"2026021706322656600_dkag055-B121","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jiac.2019.05.032","article-title":"Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients","volume":"25","author":"Yamada","year":"2019","journal-title":"J Infect Chemother"},{"key":"2026021706322656600_dkag055-B122","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/myc.13105","article-title":"Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients","volume":"63","author":"Shang","year":"2020","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B123","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1517\/13543784.15.6.579","article-title":"Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations","volume":"15","author":"Aperis","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"2026021706322656600_dkag055-B124","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2026021706322656600_dkag055-B125","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B126","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B127","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.xphs.2016.03.027","article-title":"Gastrointestinal and systemic monitoring of posaconazole in humans after fasted and fed state administration of a solid dispersion","volume":"105","author":"Hens","year":"2016","journal-title":"J Pharm Sci"},{"key":"2026021706322656600_dkag055-B128","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B129","doi-asserted-by":"publisher","first-page":"e02655-17","DOI":"10.1128\/AAC.02655-17","article-title":"Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability","volume":"62","author":"Lenczuk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B130","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.cmi.2024.07.019","article-title":"Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study","volume":"30","author":"Cao","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B131","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13054-019-2483-9","article-title":"Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients","volume":"23","author":"Sime","year":"2019","journal-title":"Crit Care"},{"key":"2026021706322656600_dkag055-B132","doi-asserted-by":"publisher","first-page":"ofae185","DOI":"10.1093\/ofid\/ofae185","article-title":"Real-world experience of posaconazole therapeutic drug monitoring in oncology patients: clinical implications of hypoalbuminemia as a predictor of subtherapeutic posaconazole levels","volume":"11","author":"Handley","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B133","doi-asserted-by":"publisher","first-page":"ofae452","DOI":"10.1093\/ofid\/ofae452","article-title":"Hypoalbuminemia and posaconazole therapeutic drug monitoring","volume":"11","author":"Nix","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B134","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/phar.70021","article-title":"Correction of posaconazole concentrations for hypoalbuminemia","volume":"45","author":"Nix","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B135","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1128\/AAC.01493-15","article-title":"Evaluation of sulfobutylether-beta-cyclodextrin exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration","volume":"59","author":"Morris","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B136","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/jac\/dkab012","article-title":"Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"76","author":"Van Daele","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B137","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jac\/dkz546","article-title":"Implications for IV posaconazole dosing in the era of obesity","volume":"75","author":"Wasmann","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B138","doi-asserted-by":"publisher","first-page":"e02465-17","DOI":"10.1128\/AAC.02465-17","article-title":"A population pharmacokinetic model for a solid oral tablet formulation of posaconazole","volume":"62","author":"van Iersel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B139","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1128\/AAC.00931-09","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B140","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"2026021706322656600_dkag055-B141","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1128\/AAC.01279-12","article-title":"Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B142","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1128\/AAC.03569-14","article-title":"Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis","volume":"58","author":"Lewis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B143","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FTD.0b013e31823cef77","article-title":"Posaconazole serum level on day 2 predicts steady state posaconazole serum level","volume":"34","author":"Green","year":"2012","journal-title":"Ther Drug Monit"},{"key":"2026021706322656600_dkag055-B144","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1128\/AAC.00389-16","article-title":"Posaconazole plasma concentrations on days three to five predict steady-state levels","volume":"60","author":"Prattes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B145","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B146","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B147","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41598-018-20136-3","article-title":"Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies","volume":"8","author":"Leclerc","year":"2018","journal-title":"Sci Rep"},{"key":"2026021706322656600_dkag055-B148","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B149","doi-asserted-by":"publisher","first-page":"e00188-17","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B150","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.cmi.2022.01.029","article-title":"Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis","volume":"28","author":"Jansen","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B151","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/jac\/dkx122","article-title":"Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation","volume":"72","author":"Pettit","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B152","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkx228","article-title":"Risk factors for subtherapeutic levels of posaconazole tablet","volume":"72","author":"Tang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B153","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijid.2022.09.004","article-title":"Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India","volume":"124","author":"Prayag","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026021706322656600_dkag055-B154","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1080\/10428194.2022.2126282","article-title":"Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients","volume":"63","author":"Bui","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026021706322656600_dkag055-B155","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/myc.12339","article-title":"Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B156","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B157","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkac035","article-title":"Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules","volume":"77","author":"Dieringer","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B158","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"2026021706322656600_dkag055-B159","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist Updat"},{"key":"2026021706322656600_dkag055-B160","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B161","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1093\/jac\/dkaa366","article-title":"Management of posaconazole-induced pseudohyperaldosteronism","volume":"75","author":"Davis","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B162","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/clpt.2010.261","article-title":"Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections","volume":"89","author":"Cornely","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2026021706322656600_dkag055-B163","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/FTD.0000000000000334","article-title":"Posaconazole therapeutic drug monitoring in a regional hospital setting","volume":"38","author":"Lindsay","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2026021706322656600_dkag055-B164","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2016.10.010","article-title":"Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis","volume":"87","author":"Cendejas-Bueno","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026021706322656600_dkag055-B165","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B166","doi-asserted-by":"publisher","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B167","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B168","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B169","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B170","doi-asserted-by":"publisher","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B171","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B172","doi-asserted-by":"publisher","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B173","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B174","doi-asserted-by":"publisher","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B175","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"Hohl","year":"2022","journal-title":"Mycoses"},{"key":"2026021706322656600_dkag055-B176","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1093\/jac\/dkaa274","article-title":"Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube","volume":"75","author":"McCreary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B177","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1093\/jac\/dkac196","article-title":"Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation","volume":"77","author":"Kriegl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B178","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2026021706322656600_dkag055-B179","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B180","doi-asserted-by":"publisher","first-page":"e01162-19","DOI":"10.1128\/aac.01162-19","article-title":"Influence of sustained low-efficiency dialysis treatment on isavuconazole plasma levels in critically ill patients","volume":"63","author":"Lahmer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B181","doi-asserted-by":"publisher","first-page":"e2019061","DOI":"10.4084\/mjhid.2019.061","article-title":"Rhino-orbital-cerebral mucormycosis after allogeneic hematopoietic stem cell transplantation and isavuconazole therapeutic drug monitoring during intestinal graft versus host disease","volume":"11","author":"Andreani","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2026021706322656600_dkag055-B182","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40261-025-01432-z","article-title":"An overview of isavuconazole clinical use: a multicentre analysis of indications, exposure and hepatic safety","volume":"45","author":"Bienvenu","year":"2025","journal-title":"Clin Drug Investig"},{"key":"2026021706322656600_dkag055-B183","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B184","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026021706322656600_dkag055-B185","doi-asserted-by":"publisher","first-page":"ofaf163","DOI":"10.1093\/ofid\/ofaf163","article-title":"Incidence of breakthrough fungal infections in patients with isavuconazole prophylaxis: a systematic review and meta-analysis","volume":"12","author":"Ishida","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B186","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B187","doi-asserted-by":"publisher","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B188","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B189","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkad328","article-title":"Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation","volume":"78","author":"Hatzl","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B190","doi-asserted-by":"publisher","first-page":"107619","DOI":"10.1016\/j.ijantimicag.2025.107619","article-title":"Therapeutic drug monitoring of isavuconazole: trends and update","volume":"66","author":"Tan","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"2026021706322656600_dkag055-B191","doi-asserted-by":"publisher","first-page":"e01511-20","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B192","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B193","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jac\/dkaf128","article-title":"Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Huang","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B194","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?","volume":"13","author":"Cojutti","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026021706322656600_dkag055-B195","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/FTD.0000000000001064","article-title":"Successful and safe real-time TDM-guided treatment of invasive pulmonary and cerebral aspergillosis using low-dose isavuconazole in a patient with primary biliary cirrhosis: grand round\/a case study","volume":"45","author":"Cojutti","year":"2023","journal-title":"Ther Drug Monit"},{"key":"2026021706322656600_dkag055-B196","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1093\/jac\/dkaf236","article-title":"Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Zhou","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B197","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","article-title":"In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model","volume":"44","author":"Andes","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B198","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1128\/AAC.00369-06","article-title":"Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect","volume":"50","author":"Hope","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B199","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cpt1978243333","article-title":"Flucytosine kinetics in subjects with normal and impaired renal function","volume":"24","author":"Cutler","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"2026021706322656600_dkag055-B200","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.11.2.244","article-title":"Bone marrow toxicity associated with 5-fluorocytosine therapy","volume":"11","author":"Kauffman","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B201","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"key":"2026021706322656600_dkag055-B202","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/AAC.2.3.114","article-title":"In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata","volume":"2","author":"Normark","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B203","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026021706322656600_dkag055-B204","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: a novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol"},{"key":"2026021706322656600_dkag055-B205","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11908-016-0549-2","article-title":"Echinocandin resistance in Candida species: a review of recent developments","volume":"18","author":"Wiederhold","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"2026021706322656600_dkag055-B206","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B207","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","article-title":"Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A Position Statement of the anti-infective drugs committee of the international association of therapeutic drug monitoring and clinical toxicology","volume":"44","author":"Kim","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2026021706322656600_dkag055-B208","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026021706322656600_dkag055-B209","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B210","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B211","doi-asserted-by":"publisher","first-page":"e00063-18","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B212","doi-asserted-by":"publisher","first-page":"e01582-16","DOI":"10.1128\/AAC.01582-16","article-title":"Low caspofungin exposure in patients in intensive care units","volume":"61","author":"van der Elst","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B213","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/1120009X.2020.1737783","article-title":"Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring?","volume":"32","author":"Adembri","year":"2020","journal-title":"J Chemother"},{"key":"2026021706322656600_dkag055-B214","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","article-title":"Altered micafungin pharmacokinetics in intensive care unit patients","volume":"59","author":"Lempers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B215","doi-asserted-by":"publisher","first-page":"e01894-16","DOI":"10.1128\/AAC.01894-16","article-title":"Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections","volume":"61","author":"Bruggemann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B216","doi-asserted-by":"publisher","first-page":"e01398-17","DOI":"10.1128\/AAC.01398-17","article-title":"Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis","volume":"61","author":"Boonstra","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B217","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B218","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"2026021706322656600_dkag055-B219","doi-asserted-by":"publisher","first-page":"e01412-17","DOI":"10.1128\/AAC.01412-17","article-title":"The gastrointestinal tract is a major source of echinocandin drug resistance in a murine model of Candida glabrata colonization and systemic dissemination","volume":"61","author":"Healey","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B220","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1586\/14787210.2015.1028366","article-title":"Impact of special patient populations on the pharmacokinetics of echinocandins","volume":"13","author":"Muilwijk","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026021706322656600_dkag055-B221","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2026021706322656600_dkag055-B222","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/10600280231175201","article-title":"Candidemia in adult patients in the ICU: a reappraisal of susceptibility testing and antifungal therapy","volume":"58","author":"Chastain","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2026021706322656600_dkag055-B223","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B224","doi-asserted-by":"publisher","first-page":"e00905-20","DOI":"10.1128\/AAC.00905-20","article-title":"Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients","volume":"64","author":"Martson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B225","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-016-0401-8","article-title":"Does weight impact anidulafungin pharmacokinetics?","volume":"55","author":"Lempers","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2026021706322656600_dkag055-B226","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","author":"Hall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B227","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1093\/ofid\/ofaa439.831","article-title":"637. Outcomes by Body Mass Index (BMI) in the STRIVE phase 2 trial of once-weekly rezafungin for treatment of candidemia and invasive candidiasis compared with caspofungin","volume":"7","author":"Vazquez","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B228","volume-title":"Outcomes by BMI in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin","author":"Vazquez","year":"2020"},{"key":"2026021706322656600_dkag055-B229","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/jof4010005","article-title":"Recent insights into the paradoxical effect of echinocandins","volume":"4","author":"Wagener","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B230","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B231","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B232","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1128\/AAC.33.9.1544","article-title":"Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice","volume":"33","author":"Gondal","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B233","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/jac\/28.suppl_B.63","article-title":"Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)","volume":"28 Suppl B","author":"Adler-Moore","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B234","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"2026021706322656600_dkag055-B235","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B236","first-page":"34","article-title":"Liposomes and lipid carriers in the treatment of microbial infections","volume":"74","author":"Bakker-Woudenberg","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"key":"2026021706322656600_dkag055-B237","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.ijid.2009.07.020","article-title":"Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome)","volume":"14 Suppl 3","author":"Watanabe","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2026021706322656600_dkag055-B238","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2026021706322656600_dkag055-B239","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/IDR.S372546","article-title":"Salvage treatment for invasive aspergillosis and mucormycosis: challenges, recommendations and future considerations","volume":"16","author":"Egger","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026021706322656600_dkag055-B240","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B241","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1128\/AAC.02226-12","article-title":"Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B242","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B243","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/08982104.2016.1205087","article-title":"Ambisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety\/efficacy","volume":"27","author":"Takemoto","year":"2017","journal-title":"J Liposome Res"},{"key":"2026021706322656600_dkag055-B244","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1348-0421.2006.tb03832.x","article-title":"Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans","volume":"50","author":"Takemoto","year":"2006","journal-title":"Microbiol Immunol"},{"key":"2026021706322656600_dkag055-B245","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B246","doi-asserted-by":"publisher","first-page":"e02526-17","DOI":"10.1128\/AAC.02526-17","article-title":"Population pharmacokinetic model and meta-analysis of outcomes of amphotericin B deoxycholate use in adults with cryptococcal meningitis","volume":"62","author":"Stott","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B247","doi-asserted-by":"publisher","first-page":"e01739-18","DOI":"10.1128\/AAC.01739-18","article-title":"Population pharmacodynamics of amphotericin B deoxycholate for disseminated infection caused by Talaromyces marneffei","volume":"63","author":"Le","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B248","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B249","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B250","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B251","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1093\/ofid\/ofab466.123","article-title":"123. Oral ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a phase 3 open-label study (FURI)","volume":"8","author":"Pappas","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B252"},{"key":"2026021706322656600_dkag055-B253","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/jof10050362","article-title":"A mini-review of in vitro data for Candida species, including C. auris, isolated during clinical trials of three new antifungals: fosmanogepix, ibrexafungerp, and rezafungin","volume":"10","author":"Espinel-Ingroff","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B254"},{"key":"2026021706322656600_dkag055-B255","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2026021706322656600_dkag055-B256","doi-asserted-by":"publisher","first-page":"100245","DOI":"10.1016\/j.crmicr.2024.100245","article-title":"Ibrexafungerp: a narrative overview","volume":"6","author":"El Ayoubi","year":"2024","journal-title":"Curr Res Microb Sci"},{"key":"2026021706322656600_dkag055-B257","doi-asserted-by":"publisher","first-page":"ofac492.064","DOI":"10.1093\/ofid\/ofac492.064","article-title":"871. Oral ibrexafungerp outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)","volume":"9","author":"Thompson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B258","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/jof8050440","article-title":"The feasibility of ibrexafungerp for the treatment of fungal infections in patients with hematological malignancies","volume":"8","author":"Daraskevicius","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B259","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026021706322656600_dkag055-B260","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jof6030122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B261","author":"Kennedy"},{"key":"2026021706322656600_dkag055-B262","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026021706322656600_dkag055-B263","doi-asserted-by":"publisher","first-page":"e01157-17","DOI":"10.1128\/mbio.01157-17","article-title":"Pharmacodynamics of the Orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"key":"2026021706322656600_dkag055-B264","doi-asserted-by":"publisher","first-page":"ofae631.1420","DOI":"10.1093\/ofid\/ofae631.1420","article-title":"P-1238. Assessment of body weight upon PK of olorofim in patients with invasive mould infections","volume":"12","author":"Cornelissen","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B265","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B266","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026021706322656600_dkag055-B267","doi-asserted-by":"publisher","first-page":"e0165023","DOI":"10.1128\/aac.01650-23","article-title":"Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B268","doi-asserted-by":"publisher","first-page":"e02542-17","DOI":"10.1128\/aac.02542-17","article-title":"In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B269","doi-asserted-by":"publisher","first-page":"e02372-18","DOI":"10.1128\/aac.02372\u201318","article-title":"APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B270","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: a phase 2, Open-Label Study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026021706322656600_dkag055-B271","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B272","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40121-022-00661-5","article-title":"Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections","volume":"11","author":"Ostrosky-Zeichner","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2026021706322656600_dkag055-B273","doi-asserted-by":"publisher","first-page":"ofad389","DOI":"10.1093\/ofid\/ofad389","article-title":"Low rates of antifungal therapeutic drug monitoring among inpatients who received itraconazole, posaconazole, or voriconazole, United States, 2019\u20132021","volume":"10","author":"Benedict","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B274","doi-asserted-by":"publisher","first-page":"ofad468","DOI":"10.1093\/ofid\/ofad468","article-title":"Antifungal therapeutic drug monitoring practices: results of an emerging infections network survey","volume":"10","author":"Benedict","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026021706322656600_dkag055-B275","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","article-title":"The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey","volume":"4","author":"Salmanton-Garcia","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026021706322656600_dkag055-B276","doi-asserted-by":"publisher","first-page":"992354","DOI":"10.3389\/fphar.2022.992354","article-title":"Therapeutic drug monitoring practices of anti-infectives: an Asia-wide cross-sectional survey","volume":"13","author":"Hou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026021706322656600_dkag055-B277","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jac5.70040","article-title":"Insights on antifungal therapeutic drug monitoring from infectious diseases physicians and hospital-based pharmacists: a focus group analysis","volume":"8","author":"Cheung","year":"2025","journal-title":"J Am Coll Clin Pharm"},{"key":"2026021706322656600_dkag055-B278","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jac\/dky389","article-title":"Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010\u201316","volume":"74","author":"Whitney","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026021706322656600_dkag055-B279","doi-asserted-by":"publisher","first-page":"dlae119","DOI":"10.1093\/jacamr\/dlae119","article-title":"Promoting antifungal stewardship through an antifungal multidisciplinary team in a paediatric and adult tertiary centre in the UK","volume":"6","author":"Soni","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026021706322656600_dkag055-B280","doi-asserted-by":"publisher","first-page":"e01245-19","DOI":"10.1128\/aac.01245-19","article-title":"Impact of triazole therapeutic drug monitoring availability and timing","volume":"63","author":"McCreary","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021706322656600_dkag055-B281","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0021-9673(02)01599-6","article-title":"Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma","volume":"987","author":"Kim","year":"2003","journal-title":"J Chromatogr A"},{"key":"2026021706322656600_dkag055-B282","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cca.2017.08.032","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite","volume":"474","author":"McShane","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2026021706322656600_dkag055-B283","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1515\/cclm-2016-0418","article-title":"A rapid UPLC-MS\/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum","volume":"55","author":"Basu","year":"2017","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag055\/66957492\/dkag055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag055\/66957492\/dkag055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:32:34Z","timestamp":1771327954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag055\/8488510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":283,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag055","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag055"}}